VIVO - Meridian Bioscience: Good Stock But Margin Of Safety Required
- Meridian Bioscience benefited from a windfall due to the Covid-19 pandemic, resulting in the growth of its Life Science segment.
- There will be a market for Covid testing in the post-Covid world, but the eventual market size of Covid testing remains uncertain.
- Its Diagnostic segment is the key to watch. We need more evidence of success.
- Hence, while we believe that this small cap has potential to be a multibagger for the long term, we require a margin of safety to mitigate the risks.
For further details see:
Meridian Bioscience: Good Stock, But Margin Of Safety Required